Wells Fargo & Company Issues Pessimistic Forecast for Alphatec (NASDAQ:ATEC) Stock Price

Key Points

• Wells Fargo cut Alphatec’s price target from $14 to $12 while maintaining an “overweight” rating. Other analysts remain broadly positive, giving the stock a consensus “Moderate Buy” rating and an average target of $16.87.
• ATEC shares fell 38.9% to $6.94, near the stock’s 12-month low of $6.81, amid concerns about Alphatec’s reduced 2026 revenue outlook and weaker bone-graft product sales.
• Third-quarter revenue rose 12.6% year over year to $221.2 million, but both revenue and EPS of $0.09 missed analyst estimates. The company continues to report losses, with analysts expecting full-year EPS of negative $0.45.

Alphatec (NASDAQ:ATEC - Get Free Report) had its price target dropped by equities researchers at Wells Fargo & Company from $14.00 to $12.00 in a report issued on Friday, Benzinga reports. The firm presently has an "overweight" rating on the medical technology company's stock. Wells Fargo & Company's price target suggests a potential upside of 72.84% from the stock's previous close.

Other equities research analysts also recently issued research reports about the company. Stephens initiated coverage on Alphatec in a report on Thursday, July 23rd. They set an "overweight" rating and a $15.00 target price for the company. Needham & Company LLC dropped their price objective on shares of Alphatec from $14.00 to $12.00 and set a "buy" rating for the company in a research note on Friday. TD Cowen reissued a "buy" rating on shares of Alphatec in a report on Friday. Weiss Ratings restated a "sell (d-)" rating on shares of Alphatec in a research report on Monday, August 3rd. Finally, BMO Capital Markets cut Alphatec from an "outperform" rating to a "market perform" rating and set a $8.00 price target for the company. in a research note on Friday. Twelve equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Alphatec presently has a consensus rating of "Moderate Buy" and a consensus target price of $16.87.

Alphatec Trading Down 38.9%

Shares of ATEC stock traded down $4.43 on Friday, hitting $6.94. The stock had a trading volume of 15,370,163 shares, compared to its average volume of 2,967,157. The company has a fifty day moving average price of $10.18 and a two-hundred day moving average price of $10.67. Alphatec has a twelve month low of $6.81 and a twelve month high of $23.29. The firm has a market cap of $1.07 billion, a P/E ratio of -9.81 and a beta of 0.78.

Alphatec (NASDAQ:ATEC - Get Free Report) last released its earnings results on Thursday, October 29th. The medical technology company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). Alphatec had a negative net margin of 13.49% and a negative return on equity of 6,752.24%. The firm had revenue of $221.17 million during the quarter, compared to the consensus estimate of $225.16 million. During the same quarter in the previous year, the firm posted $0.03 EPS. The company's revenue was up 12.6% on a year-over-year basis. On average, analysts expect that Alphatec will post -0.45 earnings per share for the current year.

Insider Activity at Alphatec

In other news, CEO Patrick Miles bought 115,000 shares of the stock in a transaction that occurred on Thursday, September 10th. The stock was acquired at an average price of $8.81 per share, with a total value of $1,013,150.00. Following the completion of the purchase, the chief executive officer directly owned 5,893,551 shares of the company's stock, valued at approximately $51,922,184.31. This represents a 1.99% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, General Counsel Tyson Marshall sold 8,168 shares of the company's stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $9.65, for a total value of $78,821.20. Following the sale, the general counsel owned 630,398 shares in the company, valued at approximately $6,083,340.70. The trade was a 1.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 13.48% of the stock is owned by company insiders.

Institutional Investors Weigh In On Alphatec

A number of large investors have recently bought and sold shares of ATEC. Summit Securities Group LLC bought a new position in shares of Alphatec in the first quarter valued at approximately $29,000. Sterling Capital Management LLC grew its holdings in Alphatec by 841.5% during the third quarter. Sterling Capital Management LLC now owns 4,105 shares of the medical technology company's stock worth $42,000 after buying an additional 3,669 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new stake in Alphatec in the 2nd quarter valued at $52,000. Allworth Financial LP lifted its stake in Alphatec by 82.6% during the 2nd quarter. Allworth Financial LP now owns 6,666 shares of the medical technology company's stock valued at $58,000 after acquiring an additional 3,015 shares in the last quarter. Finally, Atlas Brown Inc. bought a new position in Alphatec during the 2nd quarter valued at $111,000. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Alphatec

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: Third-quarter revenue increased 12.6% year over year to approximately $221.2 million, while earnings improved to $0.09 per share from $0.03 a year earlier. Management also maintained a goal of reaching a 16% adjusted EBITDA margin in 2026. Alphatec Third-Quarter Earnings Results
• Neutral Sentiment: Alphatec reported quarterly EPS of $0.09, which was higher than last year but below analyst expectations of roughly $0.10–$0.11. Revenue also fell short of the approximately $225 million consensus estimate, limiting the positive impact of year-over-year growth. Alphatec Q3 Earnings and Revenue Miss
• Negative Sentiment: The company cut its 2026 revenue forecast to $862 million, below the roughly $882 million FactSet consensus. The revision signals weaker expected growth and is the primary catalyst weighing on investor sentiment. Alphatec Lowers 2026 Revenue Outlook
• Negative Sentiment: Management attributed the outlook reduction in part to a slump in sales of add-on bone-graft products, as fewer surgeons purchased these products for spinal-fusion procedures. Investors are concerned this weakness could slow adoption of Alphatec’s broader surgical platform. Alphatec Bone-Graft Sales Slump
• Negative Sentiment: BMO Capital Markets downgraded ATEC from “outperform” to “market perform” and assigned an $8 price target. Although the target implies some potential upside from recent trading levels, the downgrade reinforces concerns about near-term execution and growth. BMO Downgrades Alphatec

Alphatec Company Profile

Alphatec Holdings, Inc is a medical technology company focused on the design, development and commercialization of products and procedural solutions for spine surgery. The company aims to improve the treatment of spinal disorders through technologies that support spinal fusion, deformity correction, reconstruction and minimally invasive procedures.

Its portfolio includes spinal implants, surgical instruments, navigation and imaging technologies, and intraoperative monitoring solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.